Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Xinnaoxin Tablet
- Development stage
- Unknown
- Lead developer
- Zhejiang Kangde Pharmaceutical Group
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Xinnaoxin Tablet (心脑欣片) is a traditional Chinese medicine (TCM) product developed and manufactured by Zhejiang Kangde Pharmaceutical. It is primarily indicated for cardiovascular and cerebrovascular conditions, including coronary heart disease, angina pectoris, and cerebral arteriosclerosis. The medication is formulated to improve blood circulation, resolve blood stasis, and nourish the heart and brain. It is an approved drug in China and is administered orally in tablet form.
- Brand names
- 心脑欣片Xinnaoxin Tablet
- Other names
- Xinnaoxin Pian
02
Targets
CA2 (Carbonic Anhydrase 2)
Beyond the preview
Go deeper on Xinnaoxin Tablet.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Xinnaoxin Tablet.